LBCA invites you this second session of a four part series on liquid biopsy/CtDNA tests and relevance for ILC.

This second webinar, in a four-part series on liquid biopsy and ILC brings together a unique panel—including surgical and medical oncologists and a patient advocate—to discuss ctDNA testing in the early stage setting. This panel will discuss current work to understand how liquid biopsies can guide surgical and treatment decisions, and monitor health after treatment. Please join us for this unique learning opportunity and a chance to ask questions.

February 11th, 12:00pm EST

Presenter(s):

Dr. Rinath Jeselsohn, LBCA Scientific Advisory Board Immediate Past Chair, Assistant Professor of Medicine at Harvard Medical School, Associate Physician of Medicine at Brigham and Women’s Hospital, and Medical Oncologist at Dana-Farber Cancer Institute

Dr. Megan Kruse, Director of Breast Medical Oncology, Co-Leader of the Breast Cancer Program, and Medical Director of the Taussig Cancer Center Clinical Trials Office at Cleveland Clinic, Scientific Advisory Board Member, Lobular Breast Cancer Alliance.

Dr. Rita Mukhtar, Professor of Clinical Surgery at the University of California, San Francisco

Barbara Neilsen, Patient Advocate

This webinar will be recorded and available to view on-demand for those unable to attend the live event.